According to reports in the literature, multiple studies have shown that the amount of cells infused was positively correlated with the therapeutic effect.[5,6] Finally, the low tumor burden of the 2 patients may be beneficial to their outcomes, although no studies have shown that the treatment efficacy of anti-BCMA CAR-T cells was related to MM tumor burden. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.